SUMMARY
CASE HISTORY
A 70-year-old, 70 kg man with symptomatic moderate to severe aortic stenosis and coronary artery disease presented for aortic valve replacement and coronary revascularisation. Echocardiography demonstrated low gradient aortic stenosis (AVA 0.7 cm 2 by continuity equation, mean gradient 34 mmHg, LV ejection fraction 30%). Coronary angiography revealed triple vessel coronary artery disease with an occluded right coronary artery, 60% left circumflex stenosis and 50% left anterior descending stenosis. Relevant comorbidities included: 1) mild chronic renal failure due to hypertensive nephrosclerosis (creatinine 124 μmol/l); 2) hypertension; 3) two previous haemorrhagic cerebrovascular accidents (eight and six years prior to this operation) with subsequent epilepsy requiring carbamazepine; 4) heavy alcohol use; 5) intermittent gout; 6) mild airflow obstruction due to smoking and 7) peripheral vascular disease causing lower limb heel ulceration. Eight years earlier his anticardiolipin IgM and IgG were less than 5 MPL and less than 5 GPL respectively. On this admission, the repeat anticardiolipin IgG was less than 10 GPL. His antibeta-2-glycoprotein was low titre (less than 20 U). Since he had no history of vascular thrombosis, he was diagnosed as having LAC without antiphospholipid syndrome (APLS).
Other haematology results were: Hb 142 g/l, platelets 250×10E 9 /l, international normalised ratio 1.2, activated partial thromboplastin time 65 seconds, fibrinogen 3.2 g/l and antithrombin activity 103%. Following uneventful induction with fentanyl, midazolam, etomidate and paralysis with pancuronium, anaesthesia was maintained with fentanyl, morphine and isoflurane. Haemodynamic monitors included invasive blood pressure, central venous pressure, pulmonary artery catheter and transoesophageal echocardiography. At induction, a bolus of tranexamic acid 2000 mg was given, followed by an infusion of 300 mg/h until protamine administration. we also performed kaolin activated clotting times (K-ACT) with an ACT Plus ® Automated Coagulation Timer System (Medtronic Australasia, Sydney, NSw) for comparison.
we used heparin for cardiopulmonary bypass (CPB) anticoagulation. The baseline celite ACT was 123 seconds and after a heparin dose of 42,000 U (600 U/kg) the celite ACT was 660 seconds. On CPB, in addition to 10,000 U of heparin in the pump prime, a heparin infusion was used at 100 U/kg/h. The total heparin dose was 68,625 U. The K-ACT read greater than 999 seconds for the duration of anticoagulation. Heparin measurement is detailed in Figures 1 and 2 .
Perfusion management included a reduced crystalloid prime adult circuit with a membrane oxygenator and roller pump. we used alpha-stat pH management with mild hypothermia to 33.6°C. The nadir haemoglobin was 75 g/l. A second dry pump setup was available in the unlikely event of uncontrolled thrombosis during CPB. The aortic valve was replaced with a 25 mm Mosaic bioprosthesis. Coronary artery grafting of the left internal mammary to the left anterior descending and saphenous vein grafts to the obtuse marginal artery and the posterior descending artery were performed.
After uneventful weaning from CPB using both dopamine and noradrenaline, heparin was reversed with protamine 300 mg by slow infusion. The celite ACT was then 117 seconds. The thromboelastograms (TEG) (kaolin and kaolin/heparinase) were then normal.
On surgical request, for subjective coagulopathy, a further 100 mg of protamine was given and an infusion of another 100 mg was given over two hours, making a total of 500 mg. One autologous blood unit of 300 ml (taken pre-bypass) was given with 1000 ml of pump blood; no other blood products were required. Postoperative recovery was unremarkable; he was commenced on a six-week course of warfarin and discharged on postoperative day 12.
DISCUSSION
Antiphospholipid syndrome is an autoimmune disorder of in vivo hypercoagulation and of importance to the cardiac anaesthetist; this subset of patients has a higher rate of perioperative thrombotic complications resulting in increased early and late morbidity and mortality following cardiac surgery 1 . Antiphospholipid antibodies and/or the LAC effect is present in 4 to 14% of the population and in 20% of those presenting with new venous thrombotic events. The LAC effect can be found in asymptomatic elderly individuals, with the highest incidence in patients with autoimmune disorders, for example systemic lupus erythematosus, where the incidence is 20 to 40%. Patients with human autoimmunodeficiency virus infection also have a high incidence, and several drugs can induce LAC, such as procainamide, hydralazine, phenytoin, quinidine and ACE inhibitors 2 .
The APLS diagnosis is established by the Sapporo criteria 3 , which are both clinical and laboratory based. The clinical criteria consist of vascular thrombosis or pregnancy morbidity and the laboratory criteria are positive tests on two or more occasions at least 12 weeks apart of 1) LAC in plasma or 2) high titre (>40 GPL or MPL) anticardiolipin or 3) anti-beta-2-glycoprotein antibodies 3, 4 . where the syndrome exists in association with a known autoimmune disorder such as systemic lupus erythematosus it is called secondary APLS and where it occurs de novo it is called primary APLS.
In patients with APLS, there is in vivo hypercoagulation which is due to many processes including activation of coagulation, inhibition of plasminogen activators/receptors (via annexin and inhibition of protein C/S and thrombomodulin), activation of platelets to enhance endothelial adherence (via induction of thromboxane A2), activation of vascular endothelium, reaction of antibodies to oxidised low-density lipoprotein, predisposing to atherosclerosis and complement activation 2 . Conversely, there is in vitro anticoagulation, due to the same antibodies prolonging clotting times in phospholipid-rich clotting tests. Due to the variety of antibodies producing the lupus anticoagulant effect, no one test is specific, however the initial indication will generally be a prolonged activated partial thromboplastin time which does not correct with the addition of normal plasma (a mixing study) suggesting the presence of an inhibitor 1 . Importantly though, prolongation in LAC assays can occur in the absence of anticardiolipin or antibeta-2-glycoprotein and the presence of these antiphospholipid antibodies does not guarantee LAC activity. This is because the antibodies producing the LAC effect react with other plasma proteins (particularly prothrombin), and beta-2-glycoprotein interacts strongly with anionic phospholipids, but weakly with phospholipids with a net neutral charge 4 . The K-ACT is the first screening test. A prolonged result is because the added phospholipids are attracted by beta-2-glycoprotein/anti-beta-2-glycoprotein complexes and decelerate activation of factors X and II 4 . Thereafter, confirmatory snake venom tests, less influenced by deficiencies or inhibitors of clotting factors are performed. Most commonly, the dilute Russell's Viper Venom Time is used and the inhibitory effects of lupus anticoagulants are overcome by adding an excess of phospholipid to the assay. This is known as 'phospholipid neutralisation' and mixing ratios of greater than 1.2 are considered positive 3 . A consensus is yet to be established for intraoperative management of anticoagulation for cardiac surgery in patients with LAC with or without APLS. Regarding anticoagulation choice for CPB, two agents have been described: heparin and bivalirudin 5, 6 . Bivalirudin has been more commonly used as a heparin substitute in the setting of APLS and heparin-induced thrombocytopenia with or without thrombosis 5, 7 . There is an association between APLS and heparin-induced thrombocytopenia 8, 9 . Disadvantages are the lack of a reversing agent in the presence of bleeding and the necessity of specialised equipment for monitoring of effect 10, 11 . Most cardiac surgical units are not equipped with an ecarin clotting time point-of-care analyser (specific for bivalirudin) 11 , although use of plasma modified ACT has been described 12 . we used heparin because we considered there to be a lower risk of heparin-induced thrombocytopenia in the absence of a significant anticardiolipin titre 8 and because the duration of action of bivalirudin is less predictable in patients with renal impairment, present in our patient. we considered heparin a more controllable anticoagulation risk in the setting of previous intracerebral haemorrhage 13, 14 , and by comparison bivalirudin has limited data in this context. In our patient 600 U/kg of heparin was required for a celite ACT of 660 seconds. we chose not to use the HepCon ® HMS Plus Hemostasis Management System (Medtronic Australasia, Sydney, NSw) for the heparin dose response as the artificially prolonged K-ACT could have underestimated the amount of heparin required 15, 16 . Measurement of adequate anticoagulation is an issue in patients with LAC. There are three methods available: the ACT, protamine titration and antifactor Xa activity. Importantly, the titration methods use differing units, either U/ml or mg/kg and the conversion from mg/kg to U/ml is 1.35. we chose two point-of-care analysers together with laboratory confirmation by heparin assay.
Our first point-of-care device was the celite ACT because usually the celite ACT is less affected by LAC than the kaolin ACT 17 . Problems with celite ACT include a narrow range of linearity due to the fixed amount of activator used, and concerns that the measured heparin concentration falls below 3 U/ml while the ACT reports a 'safe' range 16, 18 . This was shown in our case. while a minimum celite ACT of 480 is suggested, some authors have also described using the K-ACT and simply doubling the required value to greater than 999 seconds 19 .
However, this may not be appropriate given the results in our case.
Our second point-of-care analyser was the kaolin based HepCon ® HMS Plus Hemostasis Management System (Medtronic Australasia, Sydney, NSw). A celite based system such as the RxDx Hemochron System (International Technidyne Corporation, Edison, NJ, USA) was the more logical choice in LAC/APLS 17 , however this was not available for us and several authors have demonstrated the successful use of the kaolin based HepCon system 15, 20 . Importantly, we postulated that the heparin concentration would be over-estimated with this kaolin-based system and on this basis we checked the estimated heparin concentration with the established laboratory 'gold standard' of anti-factor Xa activity. The heparin concentration measured by anti-factor Xa activity was lower.
we were able to confirm the effective heparin concentration by measuring anti-factor Xa activity, as the validity of this technique has been established 21 . This test is generally used for low range heparin 0.2 to 0.8 U/ml concentrations and thus prior communication with the laboratory is needed to arrange specimen dilution and expeditious turnover time for monitoring during cardiac surgery. we used the Rotachrom ® Colorimetric Heparin Assay (Diagnostica Stago, Inc, NJ, USA) and trialled the system three times first to optimise turn-around time and dilution accuracy. However, the time from sampling to communication of result varied from 30 to 90 minutes despite this preparation.
we used tranexamic acid as an antifibrinolytic agent. Given the complex effects on the coagulation system in APLS it is difficult to judge whether antifibrinolytics are appropriate in patients with a tendency to thrombosis. In one case series of five patients where aprotinin was used, four of the patients died of thromboembolic complications 22 . The lysine analogue aminocaproic acid had been used previously in a case report by East et al 23 . The ideal dose of protamine when it is used to reverse heparin in patients with LAC has not been determined. Most authors suggest less than the normal calculated dose be given 1 and the total amount in case reports varies from around half or less of the calculated dose 19, 24 to none 22, 25 . Our approach was to titrate to effect, giving half the calculated dose and further doses titrated to a combination of surgical impression, ACT and TEG. Regarding TEG, experience in APLS comes from obstetric anaesthesia where APLS patients with abnormal activated partial thromboplastin time results present for labour epidurals. Here, preepidural TEG has been used to document safe conditions for regional anaesthesia, especially when the patient has been previously managed with heparin during the pregnancy 26 . we postulated in our patient that the R time may have been prolonged, due to kaolin and the MA artificially increased by LAC, given the prothrombotic tendency, but he showed a normal TEG result. Further studies are needed to clarify the interpretation of the TEG in patients with LAC. No obvious effects were seen in our case when autologous blood and pump blood were transfused. There is no literature on the perioperative use of autologous and pump blood in patients with LAC.
In summary, patients with LAC or APLS presenting for cardiac surgery involving CPB present complex anticoagulation problems. Consultation with a haematologist is recommended. It is important to ensure adequate anticoagulation regardless of whether heparin or bivalirudin is used during CPB, being cognisant that a greater amount of heparin may be required in these prothrombotic patients. Additionally, there are limitations to each anticoagulation measurement strategy, with assessment of heparin concentration by ACT or protamine titration with kaolin-based heparin management systems overestimating anticoagulant effect, when compared to the gold standard of anti-factor Xa activity, as shown in this case. Unfortunately, factor Xa activity may be practically difficult to use in the perioperative context. Postoperative anticoagulation should be implemented as soon as possible and warfarin has been shown to be the preferred agent 6 .
